MenAfriNet’s strategic approach is guided by a number of questions:
- What is the long-term effectiveness of meningococcal conjugate A vaccine (MACV/PsA–TT, manufactured by the Serum Institute of India, Ltd. as MenAfriVac™) against meningococcal A meningitis?
- Is there a change in the circulating organisms causing meningitis, i.e., an emergence of meningococcal epidemics due to other serogroups or additional disease due to pneumococcus?
- What is the indirect protection from MACV and how long will herd immunity protect unvaccinated cohorts?
- What are the implications for future vaccine policy and decisions about the need for a multivalent vaccine?
High-quality laboratory and case-based surveillance data, geographically and time-based epidemiologic and molecular data analysis, and special studies, using the MenAfriNet network as a platform, will be essential to answering these critical questions.